Cardiac testing leadership Transgenomic is a global leader in cardiac genetic testing with its flagship C-GAAP test, presenting a strong opportunity to cross-sell complementary molecular diagnostics and leverage existing clinical lab capabilities for expanded cardiac panels.

Threefold growth lever With three synergistic divisions—Clinical Laboratories, Pharmacogenomic Services, and Diagnostic Tools—there are multiple entry points for selling integrated solutions, reagents, and equipment to existing pharma partners, biotech customers, and academic institutions.

Clinical and trial services Pharmacogenomic and contract research services support all phases of oncology drug development, suggesting upsell opportunities to pharma and biotech customers needing companion diagnostics, biomarker validation, and scalable CRO capabilities.

Tech-enabled reach Reliance on cloud and digital tools (AWS, WordPress, Google tags, analytics) indicates potential for data-driven selling, client portals, and enhanced e-commerce for equipment, reagents, and testing services to streamline procurement for labs.

Growth via acquisitions Historical partnerships and mergers with Precipio demonstrate a track record of strategic collaborations that can be leveraged to pitch integrated solutions, co-developed assays, and expanded distribution in oncology, cardiology, and inherited disease testing.